• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

ADHD Medication During Pregnancy and Breastfeeding

Women suffering from ADHD face a difficult decision on whether to keep or stop taking ADHD medication during pregnancy and breastfeeding. There aren't enough data on how exposure to ADHD for a long time could affect the fetus.

A recent study published in Molecular Psychiatry shows that children exposed to ADHD medication in the uterus do not develop neurological developmental conditions like hearing loss or impaired vision seizures, febrile seizures, or IQ impairment. The authors acknowledge the need for higher-quality research.

Risk/Benefit Analysis

Women who are pregnant and take ADHD medication must evaluate the benefits of using it versus the risks to the foetus. Doctors don't have enough data to provide clear recommendations, but can provide information about risks and benefits to aid pregnant women in making informed decisions.

A study published in Molecular Psychiatry concluded that women who were taking ADHD medication for adhd during early pregnancy were not at greater risk of fetal malformations, or structural birth defects. Researchers used a large sample-based case control study to assess the frequency of major structural defects in infants born to mothers who took stimulants during pregnancy. Pediatric cardiologists and clinical geneticists examined the cases to ensure accurate classification of the cases and to reduce the chance of bias.

However, the study had its limitations. Most important, they were unable to separate the effects of the medication from those of the disorder at hand. This limitation makes it difficult to determine whether the limited associations observed in the groups that were exposed are due to medication use or comorbidities that cause confusion. Additionally the researchers did not look at the long-term effects of offspring on their parents.

The study did show that babies whose mothers had taken ADHD medications during pregnancy were at a greater risk of being admitted to the neonatal intensive care unit (NICU) than those who were born without any medication or had cut back on their medications prior to or during pregnancy. This was due to central nervous system disorders. The higher risk of admission was not affected by the stimulant medications used during pregnancy.

Women who were taking stimulant ADHD medication during pregnancy were also at an elevated chance of having a caesarean section or having a baby born with low Apgar score (less than 7). These risks did not appear to be influenced by the kind of medication used during pregnancy.

Researchers suggest that the minor risks associated with the use ADHD medications during early pregnancies can be offset by greater benefits for baby and mother of continued treatment for the woman’s disorder. Physicians should discuss the issue with their patients and, when possible, help them develop strategies to improve coping skills that may minimize the negative impact of her condition on her daily functioning and relationships.

Medication Interactions

As more women than ever are diagnosed with ADHD and treated with medication, the question of whether to continue or stop treatment during pregnancy is one that more and more physicians have to face. The majority of these decisions are made in the absence of solid and reliable evidence either way, so physicians have to weigh their experience about their experiences, the experiences of other doctors, and what research suggests about the subject and their own judgments for each patient.

The issue of risk for infants can be extremely difficult. The research that has been conducted on this topic is based on observation rather than controlled studies and the results are contradictory. Additionally, the majority of studies limit their analysis to live births, which could underestimate severe teratogenic effects that result in abortion or termination of the pregnancy. The study discussed in the journal club addresses these limitations by analyzing both data on live and deceased births.

The conclusion is that while some studies have shown an association between ADHD medications and the possibility of certain birth defects, others have not found any evidence of a link, and most common adhd medications studies have a neutral or slight negative effect. Therefore, a careful risk/benefit assessment must be conducted in every situation.

It isn't easy, but not impossible, for women suffering from ADHD to stop taking their medication. In fact, in a recent article in the Archives of Women's Mental Health psychologist Jennifer Russell notes that stopping Common Adhd Medications - Http://Lineyka.Org/User/Searchsharon89/, medication during pregnancy can cause depression, feelings of isolation and family conflict for patients with ADHD. Furthermore, a loss of medication for adhd and depression can affect the ability to do jobs and drive safely, which are important aspects of a normal life for many people suffering from ADHD.

She suggests that women who are not sure whether to continue taking medication or discontinue it due to pregnancy, educate their family members, colleagues, and friends about the condition, the impact on daily functioning and the advantages of staying on the current treatment plan. In addition, educating them can help the woman feel supported in her struggle with her decision. It is important to remember that some drugs can pass through the placenta, so if a woman decides to stop her ADHD medication during pregnancy and breastfeeding, she must be aware of the possibility that traces of the drug can be passed on to the baby.

Risk of Birth Defects

As the use of ADHD medication to treat the symptoms of attention deficit hyperactivity disorder (ADHD) grows as do concerns over the impact that these drugs might have on the fetuses. Recent research published in the journal Molecular Psychiatry has added to the body of knowledge regarding this issue. Researchers used two huge data sets to study more than 4.3 million pregnant women and determine if stimulant medication use caused birth defects. Researchers found that while the risk overall is low, the first trimester ADHD medication use was associated with slightly higher risk of certain heart defects, like ventriculoseptal defects.

The researchers of the study found no connection between the use of early medications and other congenital abnormalities, like facial clefting, or club foot. The findings are in line with previous studies showing the presence of a small, but significant increase in the risk of heart malformations in women who started taking ADHD medications prior to pregnancy. The risk increased in the latter half of pregnancy, when a lot of women decided to stop taking their medication.

Women who took ADHD medications in the first trimester of their pregnancies were also more likely to have caesarean sections, a low Apgar score following delivery, and a baby who needed breathing assistance during birth. The authors of the study could not remove bias in selection since they restricted the study to women who did not have any other medical conditions that could have contributed to the findings.

Researchers hope their research will inform physicians when they see pregnant women. They suggest that although a discussion of risks and benefits is important but the decision to stop or keep medication must be based on each woman's requirements and the severity of her ADHD symptoms.

The authors warn that, even though stopping the medication is an option to look into, it is not advised because of the high incidence of depression and mental health issues among women who are pregnant or who have recently given birth. Further, research shows that women who stop taking their medication will have a harder transitioning to life without them after the baby is born.

Nursing

It can be a stressful experience becoming a mother. Women suffering from ADHD can face severe challenges when they have to manage their symptoms, go to doctor appointments, prepare for the birth of their child and adjust to a new routine. Many women decide to continue taking their ADHD medication during pregnancy.

The majority of stimulant drugs pass through breast milk in low quantities, so the risk to breastfeeding infant is minimal. However, the amount of medication exposure to the newborn can vary depending on the dosage, frequency it is taken and the time of the day the medication is administered. In addition, individual medications enter the body of the baby differently through the gastrointestinal tract and breast milk. The impact of this on a newborn isn't yet fully known.

Because of the lack of evidence, some doctors may recommend stopping stimulant medications during the pregnancy of a woman. It is a difficult decision for the mother, who must weigh the benefits of her medication against the risk to the fetus. As long as there is no more information, GPs should ask all pregnant patients about their history of ADHD and whether they are planning or taking to take medication during the perinatal period.

A growing number of studies have revealed that most women can safely continue taking their ADHD medication during pregnancy and while breastfeeding. As a result, an increasing number of patients opt to do this and, in consultation with their physician, they have found that the benefits of keeping their current medication far exceed any risk.

Women who suffer from ADHD who are planning to breastfeed should seek the advice of a specialist psychiatrist prior to becoming pregnant. They should review their medications with their prescriber and discuss the advantages and disadvantages of continuing treatment, including non-pharmacological strategies. Psychoeducation is also required to help pregnant women suffering from ADHD understand their symptoms and underlying disorder and learn about treatments and to reinforce existing coping strategies. This should include a multidisciplinary approach, which includes the GP as well as obstetricians, psychiatry and obstetricians. Counselling for pregnancy should include the discussion of a treatment plan for both mother and child, as well as monitoring for signs of deterioration, and the need for adjustments to the medication regimen.